- Home
- TIXT vs DVAX Comparison
TIXT vs DVAX Comparison
Compare TIXT & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIXT
- DVAX
- Stock Information
- Founded
- TIXT 2005
- DVAX 1996
- Country
- TIXT Canada
- DVAX United States
- Employees
- TIXT N/A
- DVAX N/A
- Industry
- TIXT EDP Services
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- TIXT Technology
- DVAX Health Care
- Exchange
- TIXT Nasdaq
- DVAX Nasdaq
- Market Cap
- TIXT 1.3B
- DVAX 1.2B
- IPO Year
- TIXT 2021
- DVAX 2004
- Fundamental
- Price
- TIXT $4.49
- DVAX $9.93
- Analyst Decision
- TIXT Hold
- DVAX Buy
- Analyst Count
- TIXT 6
- DVAX 4
- Target Price
- TIXT $3.90
- DVAX $26.50
- AVG Volume (30 Days)
- TIXT 527.3K
- DVAX 1.5M
- Earning Date
- TIXT 11-07-2025
- DVAX 11-06-2025
- Dividend Yield
- TIXT N/A
- DVAX N/A
- EPS Growth
- TIXT N/A
- DVAX N/A
- EPS
- TIXT N/A
- DVAX N/A
- Revenue
- TIXT $2,718,000,000.00
- DVAX $316,268,000.00
- Revenue This Year
- TIXT $5.34
- DVAX $23.23
- Revenue Next Year
- TIXT $3.07
- DVAX $16.57
- P/E Ratio
- TIXT N/A
- DVAX N/A
- Revenue Growth
- TIXT 2.03
- DVAX 26.66
- 52 Week Low
- TIXT $2.13
- DVAX $9.20
- 52 Week High
- TIXT $4.60
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- TIXT 65.08
- DVAX 45.42
- Support Level
- TIXT $4.47
- DVAX $9.95
- Resistance Level
- TIXT $4.52
- DVAX $10.36
- Average True Range (ATR)
- TIXT 0.01
- DVAX 0.25
- MACD
- TIXT -0.02
- DVAX 0.01
- Stochastic Oscillator
- TIXT 75.00
- DVAX 35.53
About TIXT TELUS International (Cda) Inc. Subordinate Voting Shares
TELUS International (Cda) Inc is a digital customer experience innovator that designs, builds, and delivers next-generation solutions. Its clients include companies across several verticals, including Tech and Games, eCommerce and FinTech, Banking, Financial Services and Insurance, Communications and Media, and Healthcare. The solutions offered by the company include Digital Experience, Customer Experience, Advisory Services, and Back Office and Automation among other services. Geographically, it derives a majority of its revenue from the European region.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.